Press Releases

TORONTO, May 31, 2024 /PRNewswire/ - Spin Master's powerhouse franchise PAW Patrol brings home its second Golden Screen Award for Feature Film, this time for its latest theatrical PAW Patrol: The Mighty Movie. Presented by the Academy of Canadian Cinema & Television, the Golden Screen Award recognizes the Canadian film that grossed the highest in domestic box office over the period of January 1, 2022 to February 24, 2023. Produced by Spin Master Entertainment, in... (continue reading...)

BELO HORIZONTE, Brazil, May 31, 2024 (GLOBE NEWSWIRE) -- Inter&Co (NASDAQ: INTR), the leading financial super app serving over 32 million customers across the Americas, is pleased to announce that Moody's has assigned Banco Inter in Brazil with first time AA+.br long-term issuer and deposit ratings, along with a stable outlook. These debut ratings from Moodys highlight Inter's strong financial position and reflect its expanding digital retail banking model and growth... (continue reading...)

DUBLIN, IRELAND / ACCESSWIRE / May 31, 2024 / Flutter's primary listing now on the New York Stock Exchange

Flutter Entertainment plc ("Flutter" or the "Company") (NYSE: FLUT)(LSE:FLTR) announced today that its primary listing is now on the New York Stock Exchange ("NYSE"). This follows the transfer of the Company's listing category on the Official List of the Financial Conduct Authority from "Premium Listing (commercial company)" to "Standard Listing (shares)" as of... (continue reading...)

BELO HORIZONTE, Brazil, May 31, 2024 (GLOBE NEWSWIRE) -- Inter&Co (NASDAQ: INTR), the leading financial super app serving over 32 million customers across the Americas, is pleased to announce that Moody's has assigned Banco Inter in Brazil with first time AA+.br long-term issuer and deposit ratings, along with a stable outlook. These debut ratings from Moodys highlight Inter's strong financial position and reflect its expanding digital retail banking model and growth... (continue reading...)

Orally available RGT-61159 demonstrates potent inhibition of MYB synthesis and significant anti-tumor activity in a range of xenograft models of adenoid cystic carcinoma (ACC)

Data support planned first-in-human Phase 1 clinical trial of RGT-61159 in both ACC and colorectal cancer (CRC)

CAMBRIDGE, Mass., May 31, 2024 /PRNewswire/ -- Rgenta Therapeutics, a biotechnology company pioneering the development of a new class of oral small molecules for therapeutic RNA... (continue reading...)